Skip to main content

WCG Clinical, Inc. (WCGC)

WCG Clinical was planning to go public, but the IPO has been withdrawn.
Stock Price: $15.00 - $17.00
Current IPO price range

Company Description

WCG Clinical is a leading provider of clinical trial solutions, focused on providing solutions that are designed to measurably improve the quality and efficiency of clinical research, stimulate growth and foster compliance.

Our transformational solutions enable biopharmaceutical companies, contract research organizations (“CROs”), and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human protection.

Our proprietary suite of technology-enabled solutions provides ethical review services as well as broader clinical trial solutions including study planning and optimization, patient engagement, and scientific and regulatory review services.

Our solutions include software as well as technology-enabled clinical services that provide integrated, end-to-end support along the clinical trial process.

Our management estimates that over the last two years ended December 31, 2020, WCG supported approximately 90% of all global clinical trials, across a broad array of therapeutic areas and trial phases and, over the same period, our solutions have been leveraged by 87% of all new drugs and therapeutic biologics approved by the FDA.

WCG Clinical, Inc.
CountryUnited States
Founded2012
IndustryBiological Research
SectorTechnology
Employees1,322
CEODonald A. Deieso, Ph.D.

Contact Details

Address:
212 Carnegie Center, Suite 301
Princeton, NJ 08540
United States
Phone(609) 945-0101
Websitewcgclinical.com

Stock Details

Ticker SymbolWCGC
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1861104

Key Executives

NamePosition
Donald A. Deieso, Ph.D.Executive Chairman and Chief Executive Officer and Director
Nicholas SlackPresident and Chief Commercial Officer
Laurie L. JacksonChief Financial Officer and Chief Administration Officer
Barbara J. ShanderChief Legal Officer and EVP of Corporate Development
Dawn FlitcraftPresident of Ethical Review Division
John BaumerDirector
Eugene GorbachDirector
Henrik Kjær HansenDirector

Latest SEC Filings

DateTypeTitle
Oct 13, 2021RWRegistration Withdrawal Request
Aug 2, 2021S-1/AGeneral form for registration of securities under the Securities Act of 1933
Jul 27, 2021S-1/AGeneral form for registration of securities under the Securities Act of 1933
Jul 1, 2021S-1General form for registration of securities under the Securities Act of 1933
Jun 17, 2021DRS/ADraft Registration Statement
May 11, 2021DRSDraft Registration Statement
View All SEC Filings